Extending clinical partnership and scientific collaboration with University of Rome Tor Vergata
Indivumed is continuing its long-term clinical and scientific collaboration with University of Rome Tor Vergata, to create insights that help discover and develop diagnostics and therapeutics for patients with unmet need.
:quality(90))
Collaboration is the word of the day in oncology.
Last week, we had the pleasure of reconnecting with our long-term partner, the University of Rome Tor Vergata and it reminded us exactly why partnerships like this are at the heart of meaningful cancer research.
This collaboration goes far beyond a clinical partnership. Established in 2020 it is based on Tor Vergatas patient case collection according to Indivumed's defined protocols - tumor and normal biospecimen collection with minimal cold ischemia time of median under twelve minutes, adding over 300 clinical data points per patient. This is the foundation for Indivumed's analysis of comprehensive multi-omics profiles including genomics (WGS), transcriptomics, proteomics, phosphoproteomics and microRNAs from selected Tor Vergata cases. This information, together with other cases already existing in Indivumed’s IndivuType® database, are used to discover new mechanisms and biomarkers in cancer.
Rooted in years of shared scientific ambition and several scientific publications, our teams now came together for a deep dive into current projects - and aligned on exciting extensions of this already successful partnership.
As Prof. Dr. Gerry Melino, Director of the Tor Vergata Oncoscience Research Centre, puts it: "The tailoring of precision medicine according to the patient requires access to detailed information at the molecular level. In the collaboration with Indivumed we have exactly this. Through the database IndivuType® which is based on multi-omics data from highest quality biospecimen collection, we gain insights that help us discover and develop diagnostics and therapeutics that matter."
Thank you, Team Tor Vergata! The combination of translational relevance, scientific rigor, and mutual trust continues to drive our shared mission forward - for the patients who need it most.
Get insights into one of our latest joint publications focusing CRC:
https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.70023